NCT03019640
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +17 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Clinical trial condition
Refractory Follicular Lymphoma
Explore clinical trials studying Refractory Follicular Lymphoma. Study availability and eligibility vary by location and protocol.
35 public trials
6 recruiting studies
Refractory Follicular Lymphoma trial results
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +38 more
- Locations
-
- Presbyterian - Saint Lukes Medical Center - Health One Denver, Colorado, United States
- Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
- Mayo Clinic in Rochester Rochester, Minnesota, United States
- Hackensack University Medical Center Hackensack, New Jersey, United States
NCT00723099
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, +63 more
- Locations
-
- University of Colorado Hospital Aurora, Colorado, United States
- Colorado Blood Cancer Institute Denver, Colorado, United States
- LDS Hospital Salt Lake City, Utah, United States
- VA Puget Sound Health Care System Seattle, Washington, United States
Completed
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT02950220
- Conditions
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Blood Protein Disorders, Burkitt Lymphoma, +46 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
Completed
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
NCT01897012
- Conditions
- Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +36 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States